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Article summary: 
1. Ph-like ALL correlates with low CR rate, MRD persistence and poor survival in adult B-ALL 
patients also when treated in pediatric-like, MRD-driven trial. 
2 
2. The design of ad hoc front-line clinical trials is warranted in order to improve the management 
and outcome of this difficult to treat population. 
ABSTRACT 
Early recognition of Ph-like acute lymphoblastic leukemia cases could impact on the management 
and outcome of this subset of B-lineage ALL. To assess the prognostic value of the Ph-like status in 
a pediatric-inspired, minimal residual disease (MRD)-driven trial, we screened 88 B-lineage ALL 
cases negative for the major fusion genes (BCR-ABL1, ETV6-RUNX1, TCF3-PBX1 and KTM2Ar) 
enrolled in the GIMEMA LAL1913 front-line protocol for adult BCR/ABL1-negative ALL. The 
screening - performed using the “BCR/ABL1-like predictor” - identified 28 Ph-like cases (31.8%), 
characterized by CRLF2 overexpression (35.7%), JAK/STAT pathway mutations (33.3%), IKZF1 
(63.6%), BTG1 (50%) and EBF1 (27.3%) deletions, and rearrangements targeting tyrosine kinases or 
CRLF2 (40%). The correlation with outcome highlighted that: i) the complete remission (CR) rate 
was significantly lower in Ph-like compared to non-Ph-like cases (74.1% vs 91.5%, p=0.044); ii) at 
time point 2 (TP2), decisional for transplant allocation, 52.9% of Ph-like cases vs 20% of non-Ph-
like were MRD-positive (p=0.025); iii) the Ph-like profile was the only parameter associated with a 
higher risk of being MRD-positive at TP2 (p=0.014); iv) at 24 months, Ph-like patients had a 
significantly inferior event-free and disease-free survival compared to non-Ph-like patients (33.5% 
vs 66.2%, p=0.005 and 45.5% vs 72.3%, p=0.062, respectively). This study documents that Ph-like 
patients have a lower CR rate, EFS and DFS, as well as a greater MRD persistence also in a 
pediatric-oriented and MRD-driven adult ALL protocol, thus reinforcing that the early recognition 
of Ph-like ALL patients at diagnosis is crucial to refine risk-stratification and to optimize 
therapeutic strategies. 
clinicaltrials.gov: CT02067143 
3 
INTRODUCTION 
Ph-like acute lymphoblastic leukemia (ALL) accounts for 15-30% of B-lineage ALL, with an 
increasing incidence starting from adolescence. The growing interest in this subgroup of ALL arises 
from the distinctive gene expression profile - that resembles that of the true Ph-positive cases - 
and by the unfavorable clinical outcome.
1,2
 The in-depth and large-scale genetic characterization 
has shown that the majority of Ph-like ALL cases carry fusion genes involving tyrosine kinases (i.e. 
ABL-class and JAK2 rearrangements), or cytokine receptor rearrangements (i.e. P2RY8/CRLF2 and 
IGH/CRLF2), frequently associated with mutations of the JAK/STAT pathway genes.
3-5
 Among the 
other cooperating events, a relevant role is played by IKZF1 deletions present in about 70% of 
cases.
4-7
 The possibility of recognizing these cases at diagnosis has important prognostic 
implications and would also pave the way to testing tyrosine kinase inhibitors (TKI) and other 
targeted therapeutic approaches that have proven successful in pre-clinical models and in vivo in a 
few relapsed patients.
3,8-12
 So far, several strategies
13-15
 have been reported in an attempt to 
identify Ph-like cases, but none of them is deemed as the gold standard for the diagnostic work-up 
of these patients.  To this end, our group recently reported a predictive tool called “BCR/ABL1-like 
predictor” based on the levels of expression of 9 genes together with CRLF2 transcript 
quantification.
7
 From a clinical standpoint, Ph-like patients are characterized by a worse outcome 
which is due to an inferior response to induction therapy, a higher incidence of relapses and a 
lower survival.
1,2,4
 Since minimal residual disease (MRD) is considered today the most important 
prognostic factor in ALL, the role of the Ph-like status has been investigated in the context of MRD-
driven protocols, with contradicting results. Roberts and colleagues reported in a pediatric cohort 
that Ph-like patients, though displaying higher MRD levels at the end of induction, had a survival 
probability similar to that of non-Ph-like childhood ALL when treated with intensive therapies.
16
 
Opposite results were obtained by Heatley et al
14
 who demonstrated that, despite a risk-adjusted 
treatment approach, a high rate of relapse was recorded among children who were 
retrospectively identified as Ph-like. In adolescents and young adults, the results of the 
CALGB10403 trial, based on a pediatric inspired regimen, have shown that parameters associated 
with inferior survival rates were indeed represented by the Ph-like signature and obesity.
17
 In 
adult cohorts, all reported studies so far agree on a shorter survival likelihood for Ph-like ALL 
compared to non-Ph-like patients.
5-7,18,19
 However, the data are still insufficient to elucidate 
whether intensive treatments are capable of abolishing the negative impact of the Ph-like status 
on prognosis: conflicting results have been reported in the studies by Jain et al
20 
and Herold et al.
6
 
4 
Likewise, the role of the Ph-like status in the context of MRD-driven clinical trials is still unclear, 
since the data produced by the German study group were derived from a small cohort of patients.
6
 
In order to clarify these aspects, we hereby evaluated the incidence and clinico-biologic features 
of Ph-like cases - identified using the BCR/ABL1-like predictor
7
 - and the prognostic role of the Ph-
like profile in terms of CR achievement, MRD persistence and survival in a cohort of adult ALL 
patients homogeneously and intensively treated in the pediatric-oriented, MRD-driven LAL1913 
GIMEMA front-line protocol for adult Ph-negative ALL. 
 
METHODS 
Study population and experimental strategy 
This study included B-lineage ALL patients negative for major molecular aberrations (BCR/ABL1, 
KT2MA and TCF3/PBX1, B-NEG) enrolled in the GIMEMA LAL1913 front-line clinical trial 
(NCT02067143, Supplemental Figure 1) - designed for Ph-negative ALL patients aged 18-65 years - 
based on a pediatric-oriented backbone, in which Peg-Asparaginase was administered instead of 
Asparaginase, and on a MRD-driven transplant allocation
20
; MRD time-points and MRD analysis 
are detailed in Supplementary Materials and Methods. The EC study number approval is 5629. 
Diagnostic bone marrow samples were available from 105 patients (median age 38.7 years, range 
18.2-64.7). Baseline patients’ characteristics are summarized in Supplementary Table 1; there 
were no differences in clinico-biologic features between our cohort and the remaining population 
enrolled in the protocol (Supplementary Table 2). All cases underwent a centralized molecular 
screening: i) the “BCR/ABL1-like predictor” assay, ii) sequencing of the JAK/STAT and RAS cascades 
by NGS, iii) Multiplex Ligation-dependent Probe Amplification (MLPA), iv) targeted RNA 
sequencing. In 17 cases, the BCR/ABL1-like predictor was not feasible due to lack of RNA 
(Supplementary Table 3 and Supplementary Figure 2). 
 
BCR/ABL1-like predictor 
To detect the Ph-like cases, we applied the “BCR/ABL1-like predictor”
7
 to 88 patients 
(Supplementary Materials and Methods). 
 
Screening of recurrent mutations and deletions 
5 
The members of the JAK/STAT (JAK1, JAK2, JAK3, IL7R and CRLF2) and RAS (FLT3, NRAS, KRAS and 
PTPN11) pathways (181 amplicons) were sequenced by NGS (Supplementary Materials and 
Methods). 
NGS experiments were performed in 91 cases (74 in common with the BCR/ABL1-like predictor 
analysis - 24 Ph-like and 50 non-Ph-like ALL cases -, Supplementary Materials and Methods and 
Table 3). Variants recognized as single nucleotide polymorphisms (SNPs) were excluded, unless of 
prognostic value or previously reported in Ph-like ALL.
21
  
Recurrent deletions (IKZF1, CDKN2A/2B, PAX5, EBF1, BTG1, RB1, ETV6 and CRLF2)  were screened 
in 87 samples (70 in common with the BCR/ABL1-like predictor analysis - 22 Ph-like and 48 non- 
Ph-like ALL cases -, Supplemental Table 3), by the Salsa MLPA P335 ALL-IKZF1 kit (MRC-Holland, 
Amsterdam, The Netherlands) and analyzed according to Coffalyser manual.
22
 P2RY8/CRLF2 was 
inferred when a deletion within the PAR1 region was documented. Samples were defined IKZF1+ 
CDKN2A/2B and/or PAX5 when IKZF1 deletion co-occurred with CDKN2A/2B and/or PAX5 
deletions.
23
 
 
Targeted RNA-sequencing and FISH analysis  
To detect fusion genes, libraries were prepared using the TruSight RNA Pan-Cancer Panel (Illumina, 
San Diego, CA) kit, targeting 1385 cancer- genes (Supplementary Materials and Methods). 
Double-color FISH studies were performed in 20 B-ALL, 13 Ph-like and 7 non-Ph-like with high 
levels of CRLF2 expression (Supplementary Materials and Methods).  
Overall, 85 cases were screened (25 Ph-like and 60 non- Ph-like ALL cases, Supplemental Table 3). 
 
Statistical analyses 
Patients’ characteristics were compared by chi-squared or Fisher’s exact test for categorical 
variables and Wilcoxon test for continuous data. OS, DFS and EFS were estimated by the Kaplan-
Meier product-limit and compared by log-rank test. OS was defined as the time between the date 
of diagnosis and death for any cause; patients still alive were censored at the time of the last 
follow-up. DFS was defined as the time between the evaluation of CR - after the induction phase - 
and relapse or death in CR; patients still alive in first CR, were censored at the time of the last 
follow-up. Finally, EFS was defined as the time between diagnosis and non-achievement of CR in 
the induction phase, relapse or death in CR, whichever occurred first; patients still alive, in first CR, 
were censored at the time of the last follow-up. 
6 
Multivariate analysis was performed with the Cox proportional hazards regression model to adjust 
the effect of BCR/ABL1-like predictor for clinically relevant parameters (age, WBC, Hb level, 
platelet count, gender and allogeneic transplant (HSCT) and for genetic aberrations impacting on 
prognosis (IKZF1+ CDKN2A/2B and/or PAX5, K/NRAS clonal mutations, JAK/STAT clonal 
mutations).
21,22
 All tests were 2-sided, accepting p<0.05 as statistically significant. All analyses 
relied on the SAS v9.4 software. Study data were collected and managed using REDCap
24
 
electronic data capture tools hosted at the GIMEMA Foundation. 
 
RESULTS 
Incidence and clinical features of Ph-like ALL 
We identified 28 (31.8%) Ph-like cases with a median score of 0.85 (range: -0.18 - 6.37); the 
remaining 60 cases had a median score equal to -1.24 (range -1.7 - -0.33). Overall, the clinical 
features (age, gender, WBC and platelet counts) at diagnosis of Ph-like and of non-Ph-like cases 
were similar. Ph-like patients had lower hemoglobin levels (p=0.016), as detailed in Table 1. The 
incidence of Ph-like ALL cases was slightly higher in adults (≥36 years) than in young adults (18-35 
years), being 36.2% (17/47) and 26.8% (11/41), respectively. As per clinical protocol guidelines, 
only 45% of Ph-like cases were assigned to the high-risk category.  
Genetic features of Ph-like ALL cases 
The identified Ph-like cases were evaluated for the following genetic features: CRLF2 expression 
levels (n=28), JAK/STAT and RAS pathways mutations (n=24), CNA aberrations (n=22) and fusion 
genes (n=23), the latter either by RNA-sequencing and/or FISH. A CRLF2 overexpression, defined 
as ΔCt <8,25 was found in 10/28 Ph-like cases (35.7%). Among the CRLF2-high cases with a ΔCt 
value <4.5, we observed that 3 harbored a CRLF2 rearrangement, with 1 displaying a concomitant 
F232C CRLF2 mutation. Of the remaining 7 CRLF2-high cases, 3 had a concomitant rearrangement 
(2 ABL-class and 1 DDX3X/USP9X), 1 displayed a JAK1 and RAS mutation, and in 2 cases the 
mutational screening could not be performed due to lack of genomic material; finally, in 1 case no 
additional lesions were detected. Among the 24 Ph-like cases analyzed for the mutational status, 
we detected a total of 13 JAK/STAT pathway mutations - 9 clonal and 4 subclonal - in 8 cases 
(33.3%). Despite a high heterogeneity among samples, the most frequently mutated genes were 
JAK1 - affected by 5 mutations mainly targeting the hotspot V658 - and JAK2 - affected by 3 
mutations focused in the hotspot R683. IL7R and CRLF2 were mutated in 2 samples, while JAK3 
7 
only in 1. Furthermore, 6 of the 8 mutated samples (75%) displayed a concomitant CRLF2 
overexpression. Nine RAS pathway mutations - only 1 being clonal - were found in 6 patients 
(25%). The most frequent mutations (n=5) involved the hotspot G12-13 of KRAS and NRAS. CNA 
analysis in Ph-like cases revealed IKZF1, BTG1, CDKN2A/2B, PAX5 and EBF1 deletions in 14 (63.6%), 
11 (50%), 7 (31.8%), 7 (31.8%) and 6 (27.3%) cases, respectively. Furthermore, IKZF1 + CDKN2A/2B 
and PAX5 deletions, known to confer a very poor outcome, were identified in 10 cases (45.5%). 
Finally, RNA-sequencing and/or FISH experiments of the Ph-like ALL cases revealed 11 TK 
activating lesions (47.8%): 5 ABL-class fusion genes (3 NUP214/ABL1, 1 ZC3HAV1/ABL2 and 1 
EBF1/PDGFRB), 2 BCR/JAK2, 3 CRLF2-r and 1 DDX3X/USP9X, the latter known to be associated with 
CRLF2 deregulation.
26
  
Overall, Ph-like associated lesions were identified in 70.8% (17/24) of cases and are summarized in 
Table 2. 
When the genetic landscape of Ph-like ALL was compared to that of the non-Ph-like cases, 
significant differences emerged. As shown in Table 3, CRLF2-high was significantly more frequent 
in Ph-like ALL (35.7% vs 13.3%, p=0.018). Similarly, clonal JAK/STAT mutations were specific of the 
Ph-like subset (33.3% vs 4%, p=0.001), while RAS pathway clonal mutations were more frequent in 
non-Ph-like than in Ph-like ALL cases (46% vs 4.2%, p=0.001). CNAs analysis documented that 
IKZF1, EBF1 and BTG1 deletions were significantly more common of the Ph-like than in the non-Ph-
like subset (63.6%, 50% and 27.3% vs 25%, 7.8% and 2.1%, respectively; p=0.002, p<0.001 and 
p=0.007); CDKN2A/2B and PAX5 deletions were equally distributed among Ph-like and non-Ph-like 
cases (31.8% vs 47.9% and 31.8% vs 22.9%, respectively). 
The analysis of fusion genes, performed on a total of 85 patients, showed that rearrangements 
involving TKs or cytokine receptors were significantly higher in the Ph-like cases with 10 fusion 
genes involving either CRLF2 or a TK compared to only 1 CRLF2-r case in the non-BCR/ABL1-like 
cases (43.5% vs 1.6%, p<0.001). 
The genetic lesions documented in both the Ph-like and non-Ph-like subgroups are detailed in the 
Supplemental Table 3 and their distribution is provided in Figure 1; further details on non-Ph-like 
ALL cases, as well as on NGS coverage, are provided in Supplemental Results and Supplemental 
Table 5, respectively. 
Response to treatment, MRD evaluation and transplant allocation 
The Ph-like status was significantly associated with response to treatment: in fact, Ph-like patients 
had a significantly inferior CR rate at TP1 compared to non-Ph-like cases (74.1% vs 91.5%, p=0.044, 
8 
Table 4) and this translated into a lower probability of CR achievement (p=0.038, OR=0.265, CI 95% 
0.071-0.921, Supplemental Table 6). The latter data retained statistical significance also in a 
multivariate model adjusted for clinically relevant parameters, as well as for genetic lesions with a 
prognostic relevance. 
MRD evaluation - feasible in 64 patients at TP1, 62 at TP2 and 49 at TP3 - showed that at TP1, 
77.8% of Ph-like cases and 41.3% of non-Ph-like were MRD-positive (p=0.012); at TP2, 52.9% of Ph-
like cases and 20% of non-Ph-like were MRD-positive (p=0.025); similarly, at TP3, 41.7% of Ph-like 
cases and 13.5% of non-Ph-like cases were MRD-positive (p=0.05). These data, summarized in 
Table 4, indicate that in the Ph-like patients there is a significantly higher MRD persistence at all 
TPs evaluated compared to non-Ph-like cases. Consistently, the univariate analyses for MRD 
results showed that - when considering both clinically relevant parameters and genetic prognostic 
markers - only the Ph-like status was a risk factor for being MRD-positive at TP2 (p=0.014, OR=4.5, 
CI 95% 1.373-15.508) (Table 5). 
As a consequence, HSCT rate in first CR was significantly higher (p=0.015) in Ph-like vs non-Ph-like 
cases (8/20 vs 6/54, 40% vs 11%, respectively), in line with the guidelines of the trial, in which 
MRD persistence was a criterion for HSCT allocation. Importantly, among 5 MRD+ Ph-like patients 
who did not undergo a transplant, 4 relapsed at a median period a 7.8 months from CR, whereas 
no relapses occurred in the 3 MRD+ Ph-like patients undergoing HSCT. 
Survival analyses 
Survival analyses at 24 months showed that Ph-like ALL patients had a significantly inferior EFS 
than non-Ph-like patients (33.5% vs 66.2%, p=0.005); this difference was also evident with regard 
to DFS (45.5% vs 72.3%, p=0.062), though to a lesser extent, as illustrated in Figure 2; OS was also 
investigated, and although not significant, it was inferior in Ph-like ALL cases than in non-Ph-like 
patients (48.5% vs 72.9%, p=0.16, Supplemental Figure 3). The lack of significance is most likely 
due to the fact that a higher number of Ph-like patients, because of persistent MRD positivity 
underwent, as per protocol guidelines, HSCT (40% vs 11% in Ph-like vs non-Ph-like cases, 
respectively, p=0.015). 
In a multivariate model for EFS, adjusting for relevant clinical parameters - including HSCT, 
evaluated as a time dependent covariate - and genetic prognostic markers, the Ph-like profile, age 
and Hb levels were the only risk factors that retained statistical significance (Table 6). Notably, 
however, Ph-like patients undergoing an allogeneic transplant showed a trend towards better EFS 
(p=0.078). 
9 
 
DISCUSSION 
The possibility of an early recognition of Ph-like ALL patients offers the unprecedented 
opportunity to refine the prognostic categories of Ph-negative ALL, and to better understand the 
reasons for the poor outcome. In the present study, we investigated a cohort of adult B-NEG ALL 
patients enrolled in the front-line GIMEMA LAL1913 protocol,
20
 based on a pediatric-inspired 
backbone and in which MRD quantification at week 10 is pivotal for transplant allocation, in order 
to assess the prognostic impact of the Ph-like status. In particular, we aimed at understanding the 
interplay between the Ph-like status and MRD response. Furthermore, we sought to analyze the 
clinical and genetic features, the hematologic responses to treatment and the outcome of the 
identified Ph-like ALL patients. 
The screening carried out using the BCR/ABL1-like predictor
7 
led to the identification of 28 Ph-like 
cases - representing 31.8% of the B-NEG cohort - with a slightly higher incidence in adults than in 
young adults. This finding is in agreement with the recently reported data in other adult cohorts 
and resembles the epidemiologic behavior of “true Ph-positive” ALL.
5,6,19
 The comparison of the 
clinico-biologic features of Ph-like and non-Ph-like cases revealed a substantial homogeneity in 
terms of WBC count and gender distribution, as in the GMALL and the MDACC clinical trials,
6,19
 and 
at variance from Roberts and colleagues
5
 who reported that adult BCR/ABL1-like patients have a 
higher WBC and are prevalently of male gender. In children, an association with hyperleukocyotsis 
has been described by Den Boer et al
1
 and Reshmi et al
27
, the latter based on the COG AALL1131 
high-risk cohort. The association with male gender was documented in the Total Therapy XV 
cohort.
16
 On the contrary, Roberts and colleagues
28
 did not find significant differences in the WBC 
count and gender in the standard-risk subset of childhood B-ALL patients enrolled in the COG 
AALL0331. In addition to the WBC count and gender, it is worth underlying that in our study the 
population of Ph-like patients was allocated to both the standard- (56%) and high-risk (44%) 
categories: this finding has important clinical implications since the prompt identification of these 
cases might lead to a better therapeutic stratification that ultimately would avoid undertreating 
these high-risk patients. In adults, a similar distribution was reported also by Herold et al
6
, while in 
the pediatric setting this issue is still controversial. Indeed, most Ph-like cases were associated to a 
high risk in both the COALL and DCOG cohorts
1
, while in the Total Therapy XV trial
16
 Ph-like cases 
were equally distributed in the standard and high NCI risk groups. Of note, in the report on 139 
10 
children classified as standard-risk, Roberts and colleagues
28 
showed that the Ph-like status did not 
affect outcome, suggesting that in children risk stratification is clinically more significant than the 
genomic features. 
From a genetic standpoint, the present study further corroborates the notion that CRLF2 
overexpression, JAK/STAT mutations and deletions of IKZF1, BTG1 and EBF1 are significantly more 
frequent in Ph-like ALL cases. In addition, we observed that clonal JAK/STAT mutations were 
almost exclusively found in Ph-like ALL, while clonal RAS mutations were specific of non-Ph-like 
cases, thus suggesting that they play a different role in the two molecular subtypes. Moreover, 
when focusing on CRLF2 overexpression, it emerges that it is not sufficient to induce a Ph-like 
profile: indeed, of the 8 Ph-like cases that were fully characterized, 7 had at least another lesion. 
Furthermore, the results on the incidence of rearrangements targeting TKs and cytokine receptors 
indicate that they prevail in the Ph-like subgroup, with ABL-class gene rearrangements 
outnumbering the other lesions. Thus, we could identify at least 1 underlying genetic lesion in 
70.8% of Ph-like patients. Not for all cases it was possible to perform an extensive biologic 
screening due to the lack of genomic material (4 cases) and RNA-sequencing was carried out using 
targeted approaches and not genome-wide tools. This may help to explain why no further genetic 
lesions could be found in the remaining cases (29.2%) that proved positive with the BCR/ABL1 
predictor. The validity and reproducibility of the BCR-ABL1-like predictor has been externally 
validated by other institutions and from external samples in Europe, showing an overall 
concordance with other tools (FISH and NGS) of 88%.
29
 
Concerning the relationship between the Ph-like status, MRD response and outcome, we showed 
that Ph-like ALL patients have a higher risk of CR failure: in fact, 74.1% of Ph-like ALL and 91.4% 
non-Ph-like achieved a CR. This difference was not detected in the intensive GMALL trials 06/99 
and 07/03 - where all patients achieved a CR, though with a short duration -,
6
 nor in the hyper-
CVAD-based protocols or the augmented BFM regimen administered at MDACC.
19
 
More importantly, our study allowed to correlate the Ph-like status with MRD, that is presently 
regarded as the most important prognostic marker in ALL management. In fact, this analysis 
showed that in the GIMEMA LAL1913 protocol, at all TPs analyzed, the percentage of MRD-
positive patients was significantly higher in the Ph-like ALL subset than in non-Ph-like cases. This 
difference was particularly evident at TP2 (HSCT decisional point), when 52.9% of Ph-like and only 
20% of non-Ph-like cases were MRD-positive. Indeed, when both clinically relevant parameters 
and genetic prognostic markers were taken into account the Ph-like profile proved the only risk 
11 
factor for MRD positivity at TP2. Thus, considering both response to induction treatment and MRD 
monitoring, the Ph-like status, if identified early, permits not only to recognize patients who are 
likely to be refractory to induction treatment, but also to identify - within cases who achieve a CR - 
those who are likely to remain MRD-positive. This strong association may allow to anticipate 
therapeutic changes.  
To our knowledge, this is the first study that analyzes the interaction between the Ph-like status 
and MRD - assessed by quantitative polymerase chain reaction of the IG and TR gene 
rearrangements - in a broad cohort of uniformly and prospectively treated adult ALL patients 
within a clinical trial. Similar results were provided by Herold and colleagues
6
 who found that Ph-
like patients were less likely to achieve a MRD-negative status in a small cohort of 31 patients with 
overlapping MRD and Ph-like status information. In the pediatric setting, contradicting results 
have been reported.
14,16
 
Furthermore, the comparison of survival curves highlighted that Ph-like patients experienced a 
significantly worse EFS at 24 months compared to that of non-Ph-like cases (33.5% and 66.2%, 
respectively). Along the same line, also in cases achieving a CR, the Ph-like profile had a negative 
prognostic impact, as shown by the worse DFS of Ph-like patients. Although limited by the small 
sample size, our study demonstrates that transplant is beneficial in these cases and should be 
pursued at the earliest opportunity, as shown by the high rate of relapses within non-transplanted 
Ph-like patients (4/5 MRD positive patients relapsed). 
Lastly, in all outcome parameters evaluated - CR achievement, MRD at TP2 and EFS - the Ph-like 
status emerged as an independent prognostic marker. 
In addition to confirming the inferior outcome of Ph-like ALL patients, these data indicate that the 
differences between Ph-like and non-Ph-like cases are not abolished by pediatric-like intensive 
therapeutic schemes, in agreement with the results of the MDACC group.
18 
Based on the MRD 
findings hereby reported, this is primarily contributed to the significantly lower rates of complete 
molecular responses observed in Ph-like patients. 
In light of the poor outcome of Ph-like ALL and of the possibility of using targeted approaches
30
, 
different clinical trials specifically designed for Ph+ ALL and Ph-like ALL cases are testing the 
efficacy of dasatinib (NCT02420717, NCT02883049, NCT03564470, NCT02143414) or  of dasatinib 
in combination with blinatumomab (SWOG-S1318, NCT02143414). Other studies are investigating 
the impact of blinatumomab in combination with chemotherapy in Ph-negative B-lineage ALL 
(GIMEMA LAL2317- NCT03367299 and NCT02003222). In these latter studies, it is being 
12 
investigated if the addition of blinatumomab can increase the rates of CR and MRD-negativity in 
Ph-like patients, as already observed in Ph+ ALL.
32
  In support of the fact that Ph-like patients may 
benefit from targeted treatment, a recent study from Tanasi and colleagues has reported that the 
introduction of TKIs front-line was associated with a 3-years OS of 77%.
31 
Other compounds, such 
as ruxolitinib (NCT02420717, NCT03571321, NCT02723994) and the histone deacetylase inhibitor 
chidamide (NCT03564470) are under investigation. 
Taken together, the results of this study carried out on adult B-NEG ALL cases enrolled in the front-
line GIMEMA LAL1913 clinical protocol confirm that the BCR/ABL1-like predictor
7
 is a valid tool to 
rapidly recognize Ph-like cases that account for about 30% of adult B-NEG ALL. In addition, we 
could show that also in a pediatric-oriented and MRD-driven clinical trial Ph-like patients have a 
lower probability of achieving a CR, are more likely to remain MRD-positive and have a 
significantly shorter EFS. The Ph-like profile is an independent risk factor for CR failure and MRD-
persistence, thus further underlying the need that Ph-like cases - a primary unmet clinical need in 
ALL - are rapidly recognized at diagnosis in order to refine the risk stratification of Ph-negative ALL 
and optimize patients’ management. Further investigations are currently ongoing to unravel if 
within Ph-like ALL there are subgroups of patients with a different outcome likelihood. 
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Table 1. Comparison between Ph-like and non-Ph-like clinical features. 
 Ph-like non-Ph-like p-value 
N 28 60  
Age (median [range]) 42.24 [18.18-64.53] 34.52 [18.23-64.59] ns 
Wbc x10
9
/L (median [range]) 3.34 [0.23-347] 5.74 [1-75.5] ns 
Hb g/dL (median [range]) 8.70 [3.70-13.00] 9.75 [5.00-15.70] 0.034 
Plts x10
9
/L (median [range]) 40 [1.23-399] 66.5 [7.5- 630] ns 
Gender    
M 19 (67.9%) 34 (56.7%) ns 
F 9 (32.1%) 26 (43.3%) 
Risk category    
Standard risk 14 (56%) 34 (63%) ns 
No Standard risk 11 (44%) 20 (37%) 
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Record ID BCR/ABL1 -like 
prediction 
Score CRLF2 
expression 
RAS 
pathway 
status 
RAS pathway 
mutations (VAF) 
JAK/STAT 
pathway status 
JAK/STAT 
pathway mutations 
(VAF) 
IKZF1 CDKN2A/2B PAX5 IKZF1 
+CDKN2A 
and/or PAX5
BTG1 EBF1 CDKN2A/2B 
and/or RB1 
Gene 
rearrangements 
(RNAseq and/or 
FISH analysis) 
B-ALL_1 BCR/ABL1 -like 3.073 Low WT  WT  
no-Δ no-Δ no-Δ  no-Δ Δ no-Δ EBF1-PDGFRB 
B-ALL_3 BCR/ABL1 -like 0.928 Low M FLT3_ITD (5.4%) WT  Δ Δ Δ Yes no-Δ no-Δ Δ No 
B-ALL_4 BCR/ABL1 -like 0.347 Low WT  WT  
no-Δ no-Δ no-Δ  Δ no-Δ Δ No 
B-ALL_7 BCR/ABL1 -like 1.216 High WT  M clonal JAK1 DI630-631V 
(44.5%), 
JAK1V658I (35.5%) 
Δ Δ no-Δ Yes no-Δ no-Δ Δ DDX3X/USP9X 
B-ALL_16 BCR/ABL1 -like 0.788 Low WT  WT  Δ Δ Δ Yes Δ no-Δ Δ BCR/JAK2 
B-ALL_22 BCR/ABL1 -like 0.157 Low M FLT3_V491L (11.2%) WT  Δ no-Δ no-Δ  Δ no-Δ Δ NUP214/ABL1 
B-ALL_26 BCR/ABL1 -like 3.128 High M NRAS_G13D (4.1%) M clonal JAK1_V658I (35.5%) Δ no-Δ Δ Yes no-Δ Δ no−Δ No 
B-ALL_31 BCR/ABL1 -like 2.382 High WT  M clonal CRLF2_F232C 
(46.8%) 
Δ no-Δ Δ Yes no-Δ Δ no-Δ IGH/CRLF2 
B-ALL_32 BCR/ABL1 -like 5.720 Low WT  WT  
no-Δ no-Δ no-Δ  no-Δ no-Δ no-Δ NA 
B-ALL_34 
BCR/ABL1 -like 0.725 Low M PTPN11_Y279 S (1.9%); 
NRAS_G12D (2.6%); 
KRAS_G12GG (5.2%) 
WT  Δ no-Δ no-Δ  Δ no-Δ no-Δ NUP214/ABL1 
B-ALL_36 
BCR/ABL1 -like 0.205 High WT  M clonal JAK2_R683G 
(43.9%) 
Δ Δ no-Δ Yes no-Δ no-Δ Δ P2RY8/CRLF2 
B-ALL_37 BCR/ABL1 -like 0.386 Low WT  WT  
no-Δ no-Δ no-Δ  Δ Δ no-Δ No 
B-ALL_41 BCR/ABL1 -like 0.726 Low M KRAS_G12A (4.4%); 
PTPN11 V194L (4.5%) 
M clonal IL7R_INDEL (38.4%); 
JAK2_C618F (3.3%) 
Δ Δ no-Δ Yes no-Δ no-Δ Δ No 
B-ALL_44 BCR/ABL1 -like 1.587 High WT  WT  Δ no-Δ Δ Yes Δ no-Δ Δ ZC3HAV1/ABL2 
B-ALL_45 BCR/ABL1 -like 0.262 Low WT  M clonal JAK3_T21M (19.1%); 
JAK1_T688I (5.7%) 
NA NA NA  NA NA NA No 
B-ALL_46 BCR/ABL1 -like 2.449 Low WT  WT  
no-Δ no-Δ no-Δ  no-Δ no-Δ no-Δ No 
B-ALL_52 BCR/ABL1 -like 1.013 Low WT  WT  
no-Δ Δ Δ  Δ no-Δ Δ No 
B-ALL_55 BCR/ABL1 -like 0.544 Low WT  WT  
no-Δ no-Δ no-Δ  Δ no-Δ no-Δ No 
B-ALL_61 BCR/ABL1 -like 2.722 Low NA  NA  NA NA NA  NA NA NA No 
B-ALL_62 BCR/ABL1 -like 0.335 High NA  NA  NA NA NA  NA NA NA No 
B-ALL_64 BCR/ABL1 -like -0.043 Low WT  WT  NA NA NA  NA NA NA NA 
B-ALL_73 BCR/ABL1 -like 0.048 Low M clonal KRAS_G12D (35.9%) WT  Δ no-Δ no-Δ  no-Δ Δ no-Δ BCR/JAK2 
B-ALL_76 BCR/ABL1 -like 1.971 Low NA  NA  NA NA NA  NA NA NA NA 
B-ALL_81 BCR/ABL1 -like 1.150 High WT  WT  Δ Δ no-Δ Yes Δ no-Δ Δ No 
B-ALL_92 BCR/ABL1 -like -0.112 High NA  NA  NA NA NA  NA NA NA No 
B-ALL_96 BCR/ABL1 -like 6.371 High WT  M clonal CRLF2_V136M 
(60%) 
Δ no-Δ Δ Yes Δ Δ no-Δ NUP214/ABL1 
B-ALL_97 BCR/ABL1 -like 3.432 High WT  M clonal JAK2_R683G 
(10.2%); IL7R_S185C 
(18.1%); JAK1_V658F
(13.8%) 
Δ no-Δ no-Δ  Δ no−Δ no-Δ IGH/CRLF2 
B-ALL_100 BCR/ABL1 -like -0.180 Low WT  WT  
no-Δ no-Δ no-Δ  no-Δ no-Δ no-Δ No 
Table 2. Genetic features of Ph-like cases. 
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Table 3. Comparison between Ph-like and non-Ph-like genetic features. 
 BCR/ABL1-like 
non-BCR/ABL1-
p-value 
CRLF2 expression level    
CRLF2 overexpressing samples 10/28 (35.7%) 8/60 (13.3%) 0.018 
    
Mutational status    
RAS pathway mutated samples 6/24 (25%) 26/50 (52%) 0.025 
Clonal RAS mutated 1/24 (4.16%) 23/50 (46%) 0.001 
JAK/STAT pathway mutated samples 8/24 (33.3%) 7/50 (14%) 0.054 
Clonal JAK/STAT mutated 8/24 (33.3%) 2/50 (4%) 0.001 
    
Copy number aberrations    
IKZF1 deleted 14/22 (63.6%) 12/48 (25%) 0.002 
IKZF1+ CDKN2A/2B and/or PAX5 10/22 (45.5%) 7/48 (14.6%) 0.007 
BTG1 deleted 11/22 (50%) 4/48 (8.3%) <0.001 
EBF1 deleted 6/22 (27.3%) 1/48 (2.1%) 0.003 
CDKN2A/2B deleted 7/22 (31.8%) 23/48 (47.9%) ns 
PAX5 deleted 7/22 (31.8%) 11/48 (22.9%) ns 
    
TK or cytokine receptor fusion genes 10/23 (43.5%) 1/37 (2.7%) <0.001 
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Table 4. CR achievement and MRD evaluation in Ph-like and non-Ph-like cases. 
 Ph-like non-Ph-like p-value 
CR achievement    
 20 (74.1%) 54 (91.5%) 0.044 
    
TP1 (week 4)    
MRD-positive patients 14/18 (77.8%) 19/46 (41.3%) 0.012 
    
TP2 (week 10)    
MRD-positive patients 9/17 (52.9%) 9/45 (20%) 0.025 
    
TP3 (week 16)    
MRD-positive patients 5/12 (41.7%) 5/37 (13.5%) 0.05 
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Table 5. Univariate analyses for MRD at TP2, considering clinically relevant variables and 
molecular prognostic markers. 
 Univariate analysis for MRD_TP2 
 OR (95%CI) p-value 
Ph-like vs non-Ph-like 4.5 (1.373-15.508) 0.014 
Age 1.012 (0.98-1.045) 0.475 
WBC 1.013 (1-1.033) 0.133 
Plts 0.987 (0.974-0.998) 0.0365 
Hb 0.832 (0.638-1.06) 0.152 
F vs M 0.459 (0.145-1.315) 0.1602 
No SR vs SR 0.304 (0.065-1.048) 0.083 
   
IKZF1+ CDKN2A/2B and/or PAX5 vs IKZF1-only/WT 1.869 (0.49-6.674) 0.339 
Cell cycle genes deletion vs WT 0.88 (0.279-2.773) 0.8253 
RAS clonal vs WT/M subclonal 0.8 (0.239-2.51) 0.706 
JAK/STAT clonal vs WT/M subclonal 2.596 (0.463-13.293) 0.2482 
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Table 6. Summary of univariate and multivariate analyses for EFS, considering clinically relevant 
variables and molecular prognostic markers. 
 Univariate analysis for EFS Multivariate analysis for EFS 
 HR (95%CI) p-value HR (95%CI) p-value 
Ph-like vs non-Ph-like 2.6 (1.3-5.19) 0.007 2.3 (1.124-4.92) 0.023 
Age 1.03 (1.01-1.05) 0.004 1.04 (1.015-1.067) 0.002 
WBC 1.005 (0.999-1.010) 0.074   
Plts 0.993 (0.986-0.999) 0.023   
Hb 0.81 (0.69-0.94) 0.006 0.782 (0.649-0.943) 0.01 
F vs M 0.78 (0.41-1.5) 0.455   
No SR vs SR 1.89 (0.97-3.67) 0.062   
HSCT vs. No HSCT as a time 
dependendent covariate 
1.04 (0.35-3.10) 0.939   
IKZF1+ CDKN2A/2B and/or 
PAX5 vs IKZF1-only/WT 
1.73 (0.76-3.98) 0.193   
Cell cycle genes deletion vs WT 0.967 (0.451-2.069) 0.93   
RAS clonal vs WT/M subclonal 0.604 (0.269-1,358) 0.222   
JAK/STAT clonal vs WT/M 0.85 (0.26-2.82) 0.796   
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Figures legend  
Figure 1. Distribution of the genetic lesions in the Ph-like and non-Ph-like cases study; only the 
samples evaluated for the BCR/ABL1-like predictor and mutational status are depicted. 
Figure 2. Survival curves of Ph-like and non-Ph-like patients. EFS and DFS. 
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Supplementary Material and Methods 
 
 
 
MRD assessment 
 
 Time points 
MRD was defined positive if ≥10-4 for at least one IG-TR marker; it was evaluated at weeks 4 (time 
point (TP) 1), 10 (TP2), 16 (TP3) and 22 (TP4) with MRD results at week 10 (TP2) representing the 
earliest decisional TP. 
 IG/TR gene rearrangement detection 
Genomic DNA samples at diagnosis were screened by PCR amplification using the BIOMED-1 
primer sets for Ig kappa deleting element gene rearrangements IGK-Kde, complete and incomplete 
TRD and TRG gene rearrangements.1 Complete and incomplete IGH rearrangements were 
identified using 5 IGHV and 7 IGHD family primers in combination with one JH consensus primer 
according to BIOMED-2.2 Similarly, for incomplete and complete TRB gene rearrangements, the 
respective BIOMED-2 multiplex PCR primer sets were used.2 For TRD/A gene rearrangements, 
multiplex PCR primer sets were used.3 The products obtained from Ig and TCR gene 
rearrangements were further examined by heteroduplex analysis to discriminate between 
amplifications derived from monoclonal or polyclonal lymphoid cell populations.4,5 Biclonal or 
biallelic PCR products were separated either by cutting out amplicons from the polyacrylamide gel 
or by DNA cloning. 
 Sequencing and gene analysis 
The PCR products were directly sequenced using the Big Dye Terminator Cycle Sequencing 
Reaction Kit and analyzed using an automatic ABI PRISM 3130 DNA genetic analyzer (Applied 
Biosystems, Foster City, CA). The IGH, IGK, TRA TRB, TRD and TRG nucleotide sequences obtained 
were aligned to the IgBLast data base (http://www.ncbi.nlm.nih.gov/igblast/, National Cancer for 
Biotechnology Information, Bethesda, MD) and to the international ImMunoGeneTics information 
system (www.imgt. org, Initiator and Coordinator: Marie-Paule Lefranc, Montpelier, France). 
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 RQ-PCR 
Tests for residual disease were conducted by RQ-PCR amplification using TaqMan technology. The 
PCR was performed in 96-well reaction plates; ABI 7300 was the reference instrument (Applied 
Biosystems) with germline TaqMan fluorescent probes and clone-specific primers for all identified 
rearrangements.6,7 The germline probes/primers and the clone specific primers were designed for 
each target using the Primer Express (Applied Biosystems) program. The efficiency of our RQ-PCR 
assay was evaluated by calculating the slope values of the standard curve made by serially diluting 
the diagnostic DNA specimen in DNA obtained from mononuclear cells (MNC) from a pool of five 
healthy donors. The serial dilutions ranged from 10-1 to 10-5 and were tested in triplicate. MRD  
PCR targets were tested for specificity and sensitivity to select, for each patient, one target with a 
sensitivity of at least 10-4 and a quantitative range of at least 10-4, optimized for each 
rearrangement tested, both by increasing the annealing temperature and/or designing new 
primers. For normalization of the quantitative results, ALB - as the reference gene - was always 
amplified, so that all data were within a certain confidence interval and acceptability. RQ-PCR 
analyses were performed and interpreted according to the guidelines developed within the 
“EuroMRD Consortium“.8 
 
BCR/ABL1-like predictor 
This tool is based on the quantification of the 9 previously identified transcripts - SOCS2, IFITM1, 
CD99, TP53INP1, IFITM2, IGJ, NUTD4, CD97, SEMA6A - and of CRLF29 by Q-RT-PCR (SybrGreen 
method, QuantStudio5 Real-time PCR System, Thermo Fisher Scientific, Waltham, MA) and 
expression values were computed as 2^(-ΔCt). Patients with a score ≥ -0.3 were classified as Ph-
like ALL. 
 
Screening of recurrent mutations and deletions 
Sequencing libraries were prepared from 100 ng genomic DNA by using the Truseq custom 
amplicon kit (Illumina, San Diego, CA). After library quality check, samples were pooled 
equimolarly and sequenced on an Illumina MiSeq in paired-end reads of 300 bp each by using a 
MiSeq Reagent Kit v2. 
and were analyzed using the Variant Studio Software, considering only variants satisfying the 
following criteria: i) exonic variants; ii) quality of 100; iii) GQX equal to 100; iv) missense and 
truncating variants; v) read depth >100. All variants recognized as single nucleotide
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polymorphisms (SNPs) were excluded, unless a prognostic value was previously demonstrated or 
they were previously reported in Ph-like ALL.21 Furthermore, SNPs predicted as deleterious by the 
PolyPhen-2 tool were annotated. Sanger sequencing was also performed to validate selected 
variants. Exon 6 of IL7R was also sequenced by Sanger since the coverage of this hotspot was 
insufficient and chromatograms were visually inspected for the presence of INDELs by using 
Mutation Surveyor v4.0.9 (SoftGenetics, State College, PA). 
 
Targeted RNA-sequencing and FISH analysis 
After library quality check, samples were pooled equimolarly and sequenced on an Illumina MiSeq 
in paired-end reads of 76 bp each by using a MiSeq Reagent Kit v3. Fusion call was performed by 
using TopHat v1.1 and RNA-sequencing Alignment v2.0 software integrated in BaseSpace 
Sequence Hub (https://basespace.illumina.com/apps/). 
 
DNA clones for ABL1, ABL2, CSF1R, FGFR1, PDGFRB, JAK2, and TSLP tyrosin-kinases (TKs) were 
selected from the genomic databases “Ensembl” (Genome Browser, GRCh37) and “UCSC” 
(University of California, Santa Cruz, Genome Browser Feb. 2009, GRCh37/hg19), and were 
labelled by nick translation using spectrum orange and spectrum green dUTP (Abbott Molecular, 
Chicago, IL) (Supplemental Table 4). CRLF2 was studied with ZytoLight® SPEC CRLF2 Dual Color 
Break Apart Probe (ZytoVision GmbH, Bremerhaven, Germany). A clone for IL7R was used as 
internal control. Analysis was done out using a fluorescence microscope Olympus BX61 (Olympus, 
Milan, Italy) equipped with a high sensitive camera JAI (Copenhagen, Denmark) and driven by 
CytoVision 4.5.4 software (Genetix, New Milton, Hampshire, UK). At least 100 interphase nuclei 
were analyzed in each experiment. A two-step diagnostic workflow was carried out to study first, 
CRLF2 and then, in negative cases, the other TKs. Partner genes were investigated in cases with 
ABL1 or PDGFRB involvement. 
 
Supplemental results 
 
Genetic features of B-NEG ALL cohort 
NGS experiments focused on the most frequently mutated genes of the JAK/STAT and RAS 
pathway cascades. The median read depth per amplicon was 3467 reads per sample (IQR: 1124– 
5086), detailed in Supplemental Table 5. Considering the whole cohort, we found 24 JAK/STAT 
pathway mutations in 16 patients (17%), mainly affecting JAK2 - mutated in 8 cases (8.8%) - and 
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JAK1 - mutated in 6 cases (6.6%). IL7R, JAK3 and CRLF2 mutations were less common, being 
documented in 3, 2 and 2 samples, respectively. Subclonal mutations (n=13) accounted for 54.2% 
of the total. 
Overall, we detected a total of 59 RAS pathway mutations in 41 cases (45.1%), with 8 cases 
displaying >1 mutated gene and 7 cases with >1 mutation targeting the same gene. The most 
frequently affected genes were NRAS and KRAS (39 mutations): NRAS was mutated in 18 (19.8%) 
and KRAS in 15 (16.5%) cases, FLT3 proved mutated in 9 samples (9.9%) and PTPN11 in 8 cases 
(8.8%). Notably, a considerable proportion of mutations (23/59, 38.9%) were detected at the 
subclonal level (variant-allele frequency <15%). Lastly, in 9 cases the JAK/STAT and RAS cascades 
were simultaneously affected. 
In the entire B-NEG ALL cohort, we found that the most frequently deleted genes were CDKN2A/2B,  
IKZF1, PAX5 and BTG1, in 35 (40.2%), 32 (36.7%), 20 (22.9%) and 17 (19.5%) cases, respectively.  
Sixty-two % of IKZF1-deleted samples were IKZF1+ CDKN2A/2B and/or PAX5. The remaining gene deletions 
 were detected in <15% of cases. 
 
  
5 
 
References 
 
1. Pongers-Willemse MJ, Seriu T, Stolz F, et al. Primers and protocols for standardized 
detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and  
T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 
CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia. 
1999;13(1):110-118. 
2. van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR 
primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene 
recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4- 
CT98-3936. Leukemia. 2003;17(12):2257-2317. 
3. Szczepanski T, van der Velden VH, Hoogeveen PG,et al. Vdelta2-Jalpha rearrangements are 
frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells. Blood. 
2004;103(10):3798-3804. 
4. Langerak AW, Szczepański T, van der Burg M, Wolvers-Tettero IL, van Dongen JJ. 
Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect 
T cell proliferations. Leukemia. 1997;11(12):2192-2199. 
5. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease 
in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a 
Children’s Oncology Group study. Blood. 2008;111(12):5477-5485. 
6. Brüggemann M, Droese J, Bolz I, et al. Improved assessment of minimal residual disease in 
B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia. 
2000;14(8):1419-1425. 
7. Cazzaniga G, Biondi A. Molecular monitoring of childhood acute lymphoblastic leukemia 
using antigen receptor gene rearrangements and quantitative polymerase chain reaction 
technology. Haematologica. 2005;90(3):382-390. 
8. van der Velden VH, Cazzaniga G, Schrauder A, et al. Analysis of minimal residual disease by 
Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. 
Leukemia. 2007;21(4):604-611. 
9. Chiaretti S, Brugnoletti F, Messina M, et al. CRLF2 overexpression identifies an 
unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent 
genetic abnormalities. Leuk Res. 2016;41:36-42 
  
6 
 
Supplemental Table 1. Clinical feature of the cohort of study. 
 
 Whole B-NEG ALL cohort (n=105) 
Age (median [range]) 38.7 [18.2-64.7] 
WBC x 109/L (median [range]) 5.1 [0.23-347] 
Hb g/dL (median [range]) 9.4 [3.7-15.7] 
Plts x 109/L (median [range]) 56 [7.5-630] 
Gender (%)  
M 61 (58.1) 
F 44 (41.9) 
Risk (%)  
Standard risk 62 (64.6) 
No Standard risk 34 (35.4) 
CR (%)  
No CR 13 (12.6) 
CR 90 (87.4) 
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Supplemental Table 2. Clinical feature of the cohort of study in comparison with the whole 
B-NEG ALL cohort enrolled in the protocol. 
 
 
Whole B-NEG cohort 
enrolled in the 
protocol (n=115) 
Cohort studied 
for the 
BCR/ABL1-like 
predictor (n=88) 
 
p-value 
Age (median [range]) 39.08 [18.18-64.71] 37.5 [18.18-64.59] Ns 
WBC x 109/L (median [range]) 4.72 [0.23-347] 5.62 [0.23-347] Ns 
Hb g/dL (median [range]) 9.00 [3.7-15.7] 9.4 [3.7-15.7] Ns 
Plts x 109/L (median [range]) 55.5 [7.5-630] 56.5 [7.5-630]  
Gender (%)    
M 67 (58.3) 53 (60.2) 
Ns 
F 48 (41.7) 35 (39.8) 
Risk (%)    
Standard risk 69 (65.1) 48 (60.8) 
Ns 
No Standard risk 37 31 (39.2) 
CR (%)    
No CR 14 (12.5) 12 (14.0) 
Ns 
CR 98 (87.5) 74 (86.0) 
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Supplemental Table 3. List of the studies performed in each sample and summary of the 
main genetic features. 
Record ID BCR/ABL1 
like 
predictor 
BCR/ABL1 -like 
prediction 
Score CRLF2 
expression 
Mutation 
analysis 
RAS pathway 
status 
JAK/STAT 
pathway 
status 
MLPA 
analysis 
IKZF1 CDKN2A/B PAX5 IKZF1+CDKN2A 
and/or PAX5 
BTG1 EBF1 CDKN2A/2B 
and/or RB1 
TK/cytokine receptor 
fusions (RNAseq and/or 
FISH analysis) 
B-ALL_1 Yes BCR/ABL1 –like 3.073 Low Yes WT WT Yes no- no- no-  no-  no- EBF1-PDGFRB 
B-ALL_2 NA    Yes M clonal WT Yes  no- no-  no- no- no- NA 
B-ALL_3 Yes BCR/ABL1 –like 0.928 Low Yes M WT Yes    Yes no- no-  No 
B-ALL_4 Yes BCR/ABL1 –like 0.347 Low Yes WT WT Yes no- no- no-   no-  No 
B-ALL_5 Yes non-BCR/ABL1 -like -1.041 Low Yes M clonal WT Yes no- no- no-  no- no- no- No 
B-ALL_6 Yes non-BCR/ABL1 -like -1.588 Low Yes WT WT Yes no- no- no-  no- no- no- No 
B-ALL_7 Yes BCR/ABL1 –like 1.216 High Yes WT M clonal Yes   no- Yes no- no-  No 
B-ALL_8 NA    Yes WT WT Yes no- no- no-  no- no- no- NA 
B-ALL_9 Yes non-BCR/ABL1 -like -0.331 Low Yes WT WT Yes  no- no-  no- no- no- No 
B-ALL_10 Yes non-BCR/ABL1 -like -1.701 Low Yes M clonal M Yes no- no- no-  no- no- no- No 
B-ALL_11 Yes non-BCR/ABL1 -like -1.439 Low Yes WT WT Yes no-     no-  No 
B-ALL_12 Yes non-BCR/ABL1 -like -1.459 High Yes WT WT Yes no-  no-  no- no-  No 
B-ALL_13 Yes non-BCR/ABL1 -like -1.498 Low NA   NA        No 
B-ALL_14 Yes non-BCR/ABL1 -like -1.529 Low Yes M clonal WT Yes no-  no-  no- no-  No 
B-ALL_15 Yes non-BCR/ABL1 -like -1.586 Low Yes M WT Yes   no- Yes no- no-  No 
B-ALL_16 Yes BCR/ABL1 -like 0.788 Low Yes WT WT Yes    Yes  no-  BCR/JAK2 
B-ALL_17 Yes non-BCR/ABL1 -like -0.720 Low Yes WT WT Yes no- no- no-  no- no- no- No 
B-ALL_18 Yes non-BCR/ABL1 -like -1.416 Low Yes M M Yes no- no- no-  no- no- no- No 
B-ALL_19 Yes non-BCR/ABL1 -like -0.627 High Yes M WT Yes no-  no-  no- no-  No 
B-ALL_20 Yes non-BCR/ABL1 -like -0.624 Low Yes M clonal WT Yes no- no- no-  no- no- no- No 
B-ALL_21 Yes non-BCR/ABL1 -like -1.483 Low Yes M clonal WT Yes    Yes no- no-  No 
B-ALL_22 Yes BCR/ABL1 -like 0.157 Low Yes M WT Yes  no- no-   no-  NUP214/ABL1 
B-ALL_23 NA    Yes WT WT Yes    Yes no- no-  NA 
B-ALL_24 NA    Yes WT WT Yes no- no- no-  no- no- no- NA 
B-ALL_25 Yes non-BCR/ABL1 -like -0.600 High Yes WT WT Yes no- no- no-  no- no- no- No 
B-ALL_26 Yes BCR/ABL1 -like 3.128 High Yes M M clonal Yes  no-  Yes no-  no- No 
B-ALL_27 Yes non-BCR/ABL1 -like -1.324 High NA   NA        No 
B-ALL_28 Yes non-BCR/ABL1 -like -1.169 Low Yes WT WT Yes no-    no- no-  No 
B-ALL_29 Yes non-BCR/ABL1 -like -0.999 Low NA   NA        No 
B-ALL_30 NA    Yes WT WT Yes no- no- no-  no- no- no- NA 
B-ALL_31 Yes BCR/ABL1 -like 2.382 High Yes WT M clonal Yes  no-  Yes no-  no- IGH/CRLF2 
B-ALL_32 Yes BCR/ABL1 -like 5.720 Low Yes WT WT Yes no- no- no-  no- no- no- NA 
B-ALL_33 Yes non-BCR/ABL1 -like -1.153 Low Yes M clonal WT Yes  no- no-  no- no- no- No 
B-ALL_34 Yes BCR/ABL1 -like 0.725 Low Yes M WT Yes  no- no-   no- no- NUP214/ABL1 
B-ALL_35 Yes non-BCR/ABL1 -like -1.295 High Yes M clonal M clonal Yes no- no- no-  no- no- no- No only by FISH 
B-ALL_36 Yes BCR/ABL1 -like 0.205 High Yes WT M clonal Yes   no- Yes no- no-  P2RY8/CRLF2 
B-ALL_37 Yes BCR/ABL1 -like 0.386 Low Yes WT WT Yes no- no- no-    no- No 
B-ALL_38 Yes non-BCR/ABL1 -like -1.264 Low Yes WT WT Yes   no- Yes no- no-  No 
B-ALL_39 Yes non-BCR/ABL1 -like -1.520 Low Yes WT WT Yes no-  no-  no- no-  No 
B-ALL_40 Yes non-BCR/ABL1 -like -1.541 Low Yes M clonal WT Yes no-  no-  no- no-  No 
B-ALL_41 Yes BCR/ABL1 -like 0.726 Low Yes M M clonal Yes   no- Yes no- no-  No 
B-ALL_42 NA    Yes M clonal WT Yes no- no- no-   no-  NA 
B-ALL_43 Yes non-BCR/ABL1 -like -0.677 Low NA   NA        No 
B-ALL_44 Yes BCR/ABL1 -like 1.587 High Yes WT WT Yes  no-  Yes  no-  ZC3HAV1/ABL2 
B-ALL_45 Yes BCR/ABL1 -like 0.262 Low Yes WT M clonal NA        No 
B-ALL_46 Yes BCR/ABL1 -like 2.449 Low Yes WT WT Yes no- no- no-  no- no- no- No 
B-ALL_47 NA    Yes M clonal WT Yes  no- no-  no- no- no- NA 
B-ALL_48 Yes non-BCR/ABL1 -like -1.191 Low Yes WT WT Yes no- no- no-  no- no- no- No 
B-ALL_49 NA    Yes M clonal WT Yes no- no- no-  no- no- no- NA 
B-ALL_50 Yes non-BCR/ABL1 -like -1.417 Low Yes M clonal WT Yes no- no- no-  no- no- no- No 
B-ALL_51 Yes non-BCR/ABL1 -like -1.537 High NA   NA        No only by FISH 
B-ALL_52 Yes BCR/ABL1 -like 1.013 Low Yes WT WT Yes no-     no-  No 
B-ALL_53 Yes non-BCR/ABL1 -like -0.497 Low Yes WT WT Yes no-     no-  No 
B-ALL_54 Yes non-BCR/ABL1 -like -1.636 Low Yes M clonal WT Yes no-    no- no-  No 
B-ALL_55 Yes BCR/ABL1 -like 0.544 Low Yes WT WT Yes no- no- no-   no- no- No 
B-ALL_56 Yes non-BCR/ABL1 -like -1.071 Low Yes WT WT Yes  no- no-  no- no- no- No 
B-ALL_57 Yes non-BCR/ABL1 -like -1.468 Low Yes WT WT Yes no- no- no-  no- no- no- No 
B-ALL_58 Yes non-BCR/ABL1 -like -1.180 Low Yes M clonal WT Yes no-  no-  no- no-  No 
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B-ALL_59 Yes non-BCR/ABL1 -like -1.202 High Yes WT WT NA        IGH/CRLF2 
B-ALL_60 Yes non-BCR/ABL1 -like -1.390 Low Yes WT WT Yes  no- no-  no- no- no- No 
B-ALL_61 Yes BCR/ABL1 -like 2.722 Low NA   NA        No 
B-ALL_62 Yes BCR/ABL1 -like 0.335 High NA   NA        No 
B-ALL_63 NA    Yes WT WT Yes  no- no-  no- no- no- NA 
B-ALL_64 Yes BCR/ABL1 -like -0.043 Low Yes WT WT NA        NA 
B-ALL_65 NA    Yes WT WT Yes no- no- no-  no- no- no- NA 
B-ALL_66 NA    Yes M clonal WT Yes no-  no-  no- no-  NA 
B-ALL_67 NA    Yes M clonal M Yes no- no- no-  no- no- no- NA 
B-ALL_68 Yes non-BCR/ABL1 -like -1.119 Low Yes WT M Yes    Yes no- no-  No 
B-ALL_69 Yes non-BCR/ABL1 -like -1.298 Low Yes M clonal WT Yes no- no- no-  no- no-  No 
B-ALL_70 NA    Yes WT WT Yes    Yes  no-  NA 
B-ALL_71 NA    Yes M clonal WT Yes no-  no-  no- no-  NA 
B-ALL_72 NA    Yes M clonal WT Yes no- no- no-  no- no- no- NA 
B-ALL_73 Yes BCR/ABL1 -like 0.048 Low Yes M clonal WT Yes  no- no-  no-  no- BCR/JAK2 
B-ALL_74 Yes non-BCR/ABL1 -like -1.196 Low Yes M clonal WT Yes  no- no-  no- no- no- No 
B-ALL_75 Yes non-BCR/ABL1 -like -0.492 Low Yes M clonal WT Yes no- no-    no- no- No 
B-ALL_76 Yes BCR/ABL1 -like 1.971 Low NA   NA        NA 
B-ALL_77 Yes non-BCR/ABL1 -like -1.562 Low Yes M clonal WT Yes no-       No 
B-ALL_78 Yes non-BCR/ABL1 -like -1.172 Low NA   NA        No 
B-ALL_79 Yes non-BCR/ABL1 -like -1.486 Low Yes M clonal WT NA        No 
B-ALL_80 Yes non-BCR/ABL1 -like -1.248 High Yes M clonal M clonal Yes   no- Yes no- no-  No 
B-ALL_81 Yes BCR/ABL1 -like 1.150 High Yes WT WT Yes   no- Yes  no-  No 
B-ALL_82 Yes non-BCR/ABL1 -like -1.522 Low Yes M clonal WT Yes no-  no-  no- no-  No 
B-ALL_83 Yes non-BCR/ABL1 -like -1.672 Low Yes WT WT Yes no- no- no-  no- no- no- No 
B-ALL_84 NA    Yes WT WT Yes no- no- no-  no- no- no- NA 
B-ALL_85 Yes non-BCR/ABL1 -like -0.400 Low Yes WT WT Yes no- no- no-  no- no- no- No 
B-ALL_86 Yes non-BCR/ABL1 -like -1.150 Low NA   NA        No 
B-ALL_87 NA    Yes M clonal WT Yes   no- Yes no- no-  NA 
B-ALL_88 Yes non-BCR/ABL1 -like -1.235 Low Yes WT WT Yes no-    no- no-  No 
B-ALL_89 Yes non-BCR/ABL1 -like -1.103 Low Yes M clonal M Yes no- no- no-  no- no- no- No 
B-ALL_90 Yes non-BCR/ABL1 -like -1.027 Low NA   NA        No 
B-ALL_91 Yes non-BCR/ABL1 -like -1.310 Low Yes M clonal M Yes    Yes no- no-  No 
B-ALL_92 Yes BCR/ABL1 -like -0.112 High NA   NA        No 
B-ALL_93 Yes non-BCR/ABL1 -like -1.232 Low NA   NA        No 
B-ALL_94 Yes non-BCR/ABL1 -like -1.398 Low Yes WT WT Yes   no- Yes no- no-  No 
B-ALL_95 Yes non-BCR/ABL1 -like -1.411 Low NA   NA        No 
B-ALL_96 Yes BCR/ABL1 -like 6.371 High Yes WT M clonal Yes  no-  Yes   no- NUP214/ABL1 
B-ALL_97 Yes BCR/ABL1 -like 3.432 High Yes WT M clonal Yes  no- no-   no- no- IGH/CRLF2 
B-ALL_98 Yes non-BCR/ABL1 -like -1.563 Low Yes M clonal WT Yes no-  no-  no- no-  No 
B-ALL_99 Yes non-BCR/ABL1 -like -0.835 Low Yes WT WT Yes no- no- no-  no- no- no- No 
B-ALL_100 Yes BCR/ABL1 -like -0.180 Low Yes WT WT Yes no- no- no-  no- no- no- No 
B-ALL_101 Yes non-BCR/ABL1 -like -1.420 Low Yes M clonal WT Yes no- no- no-  no- no- no- No 
B-ALL_102 Yes non-BCR/ABL1 -like -1.534 Low Yes M clonal WT Yes no- no- no-  no- no- no- No 
B-ALL_103 Yes non-BCR/ABL1 -like -1.658 Low Yes WT WT Yes no-    no- no-  No 
B-ALL_104 Yes non-BCR/ABL1 -like -1.557 Low Yes WT WT Yes no-  no-  no- no-  No 
B-ALL_105 Yes non-BCR/ABL1 -like -1.623 Low Yes WT WT Yes no- no- no-  no- no- no- No 
 
Supplemental Table 4. FISH probes. 
 
  Genomic clones 
Kinase Mapping Centromeric Spanning Telomeric 
ABL2 1q25 RP11-177A2  RP11-345I18 
IL7R 5p13 RP11-974M7   
TSLP 5q22  RP11-746A23  
 
PDGFRB 
 
5q32 
LSI PDGFRB Dual Color, Break 
Apart (Vysis, Abbott) 
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CSF1R 5q32 RP11-100O5  RP11-432O16 
FGFR1 8p11 RP11-359P11  RP11-513D5 
  RP11-495O10  RP11-265K5 
JAK2 9p24 RP11-39K24  RP11-125K10 
ABL1 9q34 RP11-57C19  RP11-83J21 
     
Partners     
TNIP1 5q33.1 RP11-915J10  RP11-632E9 
EBF1 5q33.3 RP11-1019K12  RP11-583A20 
NUP214 9q34 RP11-143H20 RP11-544A12  
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Supplemental Table 5. Median coverage per sample itemized by amplicon. Amplicons 
are indicated by chromosome and start/end coordinates according to GRCh37/hg19. 
Amplicon ID Chromosome Start End Median read depth per 
sample 
Target Exon CCDS 
CRLF2 + CRLF2_UserDefined (47131292)_140707109 chrX 1314870 1315034 3188.50 EX6 75945.1 
CRLF2 + CRLF2_UserDefined (47229427)_140707061 chrX 1325306 1325512 1763.50 EX3 75945.1 
CRLF2 + CRLF2_UserDefined (47229427)_140707062 chrX 1325306 1325512 5066.00 EX3 75945.1 
CRLF2_Cds_17104068_UserDefined (47229428)_140707063 chrX 1331429 1331547 6125.00 EX1 75945.1 
CRLF2_Cds_17104572_UserDefined (47229425)_140707058 chrX 1317399 1317601 1386.00 EX5 75945.1 
CRLF2_Cds_17104572_UserDefined (47229425)_140707059 chrX 1317399 1317601 5341.50 EX5 75945.1 
CRLF2_Cds_17104572_UserDefined (47229425)_140707059 chrX 1317399 1317601 272.50 EX5 75945.1 
CRLF2_Cds_17105645_UserDefined (47229426)_140707060 chrX 1321252 1321425 97.00 Ex4 75945.1 
CRLF2_Cds_17108029_UserDefined (47229374)_140706942 chrX 1327679 1327821 138.50 Ex2 75945.1 
FLT3 + FLT3 + FLT3_UserDefined (47229379)_140706972 chr13 28608004 28608564 3867.50 EX13,14,15 31953.1 
FLT3 + FLT3 + FLT3_UserDefined (47229379)_140706973 chr13 28608004 28608564 7544.00 EX13,14,15 31953.1 
FLT3 + FLT3 + FLT3_UserDefined (47229379)_140706974 chr13 28608004 28608564 8473.00 EX13,14,15 31953.1 
FLT3 + FLT3 + FLT3_UserDefined (47229379)_140706975 chr13 28608004 28608564 5510.00 EX13,14,15 31953.1 
FLT3 + FLT3_UserDefined (47132139)_140706976 chr13 28609612 28610200 1858.50 EX11,12 31953.1 
FLT3 + FLT3_UserDefined (47132139)_140706977 chr13 28609612 28610200 2586.50 EX11,12 31953.1 
FLT3 + FLT3_UserDefined (47132139)_140706978 chr13 28609612 28610200 4771.50 EX11,12 31953.1 
FLT3 + FLT3_UserDefined (47132139)_140706979 chr13 28609612 28610200 4137.00 EX11,12 31953.1 
FLT3 + FLT3_UserDefined (47229380)_140706980 chr13 28623501 28623931 379.00 EX7,8 31953.1 
FLT3 + FLT3_UserDefined (47229380)_140706981 chr13 28623501 28623931 5173.00 EX7,8 31953.1 
FLT3 + FLT3_UserDefined (47229380)_140706982 chr13 28623501 28623931 6367.00 EX7,8 31953.1 
FLT3_Cds_16768078_UserDefined (47132129)_140706943 chr13 28611302 28611445 7255.00 EX10 31953.1 
FLT3_Cds_16768110_UserDefined (47229408)_140707032 chr13 28622392 28622600 2194.00 EX9 31953.1 
FLT3_Cds_16768110_UserDefined (47229408)_140707033 chr13 28622392 28622600 3821.00 Ex9 31953.1 
FLT3_Cds_16768173_UserDefined (47229409)_140707034 chr13 28624212 28624379 6360.00 EX6 31953.1 
FLT3_Cds_16768912_UserDefined (47131202)_140707037 chr13 28635984 28636226 3693.50 EX3 31953.1 
FLT3_Cds_16768912_UserDefined (47131202)_140707038 chr13 28635984 28636226 6962.50 EX3 31953.1 
FLT3_Cds_16768942_UserDefined (47229413)_140707040 chr13 28674585 28674667 150.00 Ex1 31953.1 
FLT3_Cds_16769202_UserDefined (47229406)_140707030 chr13 28601205 28601398 7894.50 EX17 31953.1 
FLT3_Cds_16769656_UserDefined (47229411)_140707036 chr13 28631464 28631619 2173.50 EX4 31953.1 
FLT3_Cds_16769738_UserDefined (47229410)_140707035 chr13 28626662 28626831 567.00 EX5 31953.1 
FLT3_Cds_16770190_UserDefined (47131204)_140707025 chr13 28589707 28589858 460.50 Ex21 31953.1 
FLT3_Cds_16770364_UserDefined (47229412)_140707039 chr13 28644608 28644769 864.00 EX2 31953.1 
FLT3_Cds_16770538_UserDefined (47229403)_140707026 chr13 28592584 28592746 5156.50 EX20 31953.1 
FLT3_Cds_16770619_UserDefined (47229405)_140707029 chr13 28598978 28599100 127.50 Ex18 31953.1 
FLT3_Cds_16770758_UserDefined (47229407)_140707031 chr13 28602295 28602445 244.00 Ex16 31953.1 
FLT3_Cds_16772090_UserDefined (47229402)_140707024 chr13 28589274 28589413 6930.50 EX22 31953.1 
FLT3_Cds_16772363_UserDefined (47229401)_140707023 chr13 28588569 28588714 1914.00 EX23 31953.1 
FLT3_Cds_16773285_UserDefined (47229404)_140707027 chr13 28597467 28597634 4068.50 EX19 31953.1 
FLT3_Cds_16773285_UserDefined (47229404)_140707028 chr13 28597467 28597634 6348.50 EX19 31953.1 
FLT3_Cds_16773901_UserDefined (47229453)_140707108 chr13 28578172 28578331 7226.00 EX24 31953.1 
IL7R_Cds_17002546_UserDefined (47229432)_140707067 chr5 35871138 35871335 2252.00 Ex4 3911.1 
IL7R_Cds_17003436_UserDefined (47229431)_140707066 chr5 35867388 35867585 625.50 Ex3 3911.1 
IL7R_Cds_17004661_UserDefined (47229430)_140707065 chr5 35860934 35861112 4317.50 Ex2 3911.1 
IL7R_Cds_17006734_UserDefined (47229429)_140707064 chr5 35857060 35857181 471.50 Ex1 3911.1 
IL7R_Cds_17007143_UserDefined (47229455)_140707115 chr5 35876065 35876605 109.00 Ex8 3911.1 
IL7R_Cds_17007143_UserDefined (47229455)_140707116 chr5 35876065 35876605 241.00 Ex8 3911.1 
IL7R_Cds_17007143_UserDefined (47229455)_140707117 chr5 35876065 35876605 6207.00 EX8 3911.1 
IL7R_Cds_17007407_UserDefined (47229433)_140707068 chr5 35873562 35873770 4700.00 Ex5 3911.1 
IL7R_Cds_17007407_UserDefined (47229433)_140707069 chr5 35873562 35873770 6925.50 Ex5 3911.1 
IL7R_Cds_17008069_UserDefined (47229434)_140707070 chr5 35874531 35874664 43.50 Ex6 3911.1 
IL7R_Cds_17008455_UserDefined (47132221)_140707114 chr5 35875594 35875709 3216.50 EX7 3911.1 
JAK1 + JAK1_UserDefined (47131288)_140706987 chr1 65306908 65307304 4772.00 EX17,18 41346.1 
JAK1 + JAK1_UserDefined (47131288)_140706988 chr1 65306908 65307304 43.50 EX17,18 41346.1 
JAK1_Cds_16667511_UserDefined (47229436)_140707073 chr1 65303595 65303807 5756.00 EX21 41346.1 
JAK1_Cds_16667511_UserDefined (47229436)_140707074 chr1 65303595 65303807 2611.00 EX21 41346.1 
JAK1_Cds_16668160_UserDefined (47131254)_140707075 chr1 65304128 65304292 2640.50 EX20 41346.1 
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JAK1_Cds_16668437_UserDefined (47229435)_140707071 chr1 65301059 65301209 1186.50 EX23 41346.1 
JAK1_Cds_16668664_UserDefined (47229448)_140707097 chr1 65348940 65349178 2564.00 EX2 41346.1 
JAK1_Cds_16668664_UserDefined (47229448)_140707098 chr1 65348940 65349178 3595.00 EX2 41346.1 
JAK1_Cds_16668729_UserDefined (47229446)_140707091 chr1 65332529 65332911 7072.00 EX6 41346.1 
JAK1_Cds_16668729_UserDefined (47229446)_140707092 chr1 65332529 65332911 6445.50 EX6 41346.1 
JAK1_Cds_16668896_UserDefined (47229441)_140707081 chr1 65312312 65312439 1012.50 EX13 41346.1 
JAK1_Cds_16669432_UserDefined (47131256)_140707118 chr1 65300228 65300360 4055.50 EX24 41346.1 
JAK1_Cds_16669868_UserDefined (47131268)_140707093 chr1 65334974 65335177 3677.50 EX5 41346.1 
JAK1_Cds_16669993_UserDefined (47229443)_140707083 chr1 65316467 65316613 4800.50 EX11 41346.1 
JAK1_Cds_16670263_UserDefined (47229440)_140707080 chr1 65311176 65311343 709.00 EX14 41346.1 
JAK1_Cds_16670566_UserDefined (47131258)_140707089 chr1 65330450 65330675 3741.00 EX7 41346.1 
JAK1_Cds_16670566_UserDefined (47131258)_140707090 chr1 65330450 65330675 4244.00 EX7 41346.1 
JAK1_Cds_16670758_UserDefined (47229447)_140707094 chr1 65339033 65339226 4466.50 EX4 41346.1 
JAK1_Cds_16670758_UserDefined (47229447)_140707095 chr1 65339033 65339226 2156.50 EX4 41346.1 
JAK1_Cds_16671022_UserDefined (47229445)_140707087 chr1 65325768 65325965 5669.50 EX8 41346.1 
JAK1_Cds_16671022_UserDefined (47229445)_140707088 chr1 65325768 65325965 3150.50 EX8 41346.1 
JAK1_Cds_16671238_UserDefined (47229444)_140707084 chr1 65321172 65321401 5527.50 EX10 41346.1 
JAK1_Cds_16671238_UserDefined (47229444)_140707085 chr1 65321172 65321401 3457.00 EX10 41346.1 
JAK1_Cds_16671455_UserDefined (47229442)_140707082 chr1 65313195 65313378 3702.50 EX12 41346.1 
JAK1_Cds_16671565_UserDefined (47229439)_140707079 chr1 65310417 65310592 1402.00 EX15 41346.1 
JAK1_Cds_16671602_UserDefined (47131252)_140707072 chr1 65301761 65301918 4786.00 EX22 41346.1 
JAK1_Cds_16671956_UserDefined (47229438)_140707078 chr1 65309727 65309918 8625.50 EX22 41346.1 
JAK1_Cds_16672003_UserDefined (47229437)_140707076 chr1 65305266 65305498 354.00 EX19 41346.1 
JAK1_Cds_16672003_UserDefined (47229437)_140707077 chr1 65305266 65305498 494.50 EX19 41346.1 
JAK1_Cds_16672014_UserDefined (47131262)_140707096 chr1 65344688 65344851 2996.50 EX3 41346.1 
JAK1_Cds_16672393_UserDefined (47131272)_140707099 chr1 65351922 65351967 2898.00 EX1 41346.1 
JAK1_Cds_16672446_UserDefined (47132208)_140707086 chr1 65323319 65323482 3368.50 EX9 41346.1 
JAK2 + JAK2_UserDefined (47229375)_140706944 chr9 5080209 5080703 3969.00 EX15,16 6457.1 
JAK2 + JAK2_UserDefined (47229375)_140706945 chr9 5080209 5080703 3622.50 EX15,16 6457.1 
JAK2 + JAK2_UserDefined (47229375)_140706946 chr9 5080209 5080703 5232.00 EX15,16 6457.1 
JAK2 + JAK2_UserDefined (47229449)_140707100 chr9 5126313 5126808 3888.50 EX22,23 6457.1 
JAK2 + JAK2_UserDefined (47229449)_140707101 chr9 5126313 5126808 4304.50 EX22,23 6457.1 
JAK2 + JAK2_UserDefined (47229449)_140707102 chr9 5126313 5126808 3657.00 EX22,23 6457.1 
JAK2 + JAK2_UserDefined (47229454)_140707110 chr9 5090347 5091015 4185.50 EX19,20 6457.1 
JAK2 + JAK2_UserDefined (47229454)_140707111 chr9 5090347 5091015 5543.00 EX19,20 6457.1 
JAK2 + JAK2_UserDefined (47229454)_140707112 chr9 5090347 5091015 319.50 EX19,20 6457.1 
JAK2 + JAK2_UserDefined (47229454)_140707113 chr9 5090347 5091015 4606.00 EX19,20 6457.1 
JAK2_Cds_17086073_UserDefined (47229385)_140706993 chr9 5050666 5050851 2780.00 EX4 6457.1 
JAK2_Cds_17086073_UserDefined (47229385)_140706994 chr9 5050666 5050851 125.00 EX4 6457.1 
JAK2_Cds_17086074_UserDefined (47229393)_140707010 chr9 5089654 5089883 314.00 EX18 6457.1 
JAK2_Cds_17086074_UserDefined (47229393)_140707011 chr9 5089654 5089883 2120.00 EX18 6457.1 
JAK2_Cds_17086262_UserDefined (47229382)_140706989 chr9 5021968 5022233 1241.50 EX1 6457.1 
JAK2_Cds_17086262_UserDefined (47229382)_140706990 chr9 5021968 5022233 6433.50 EX1 6457.1 
JAK2_Cds_17087236_UserDefined (47229392)_140707009 chr9 5081705 5081881 178.50 EX17 6457.1 
JAK2_Cds_17087477_UserDefined (47229394)_140707012 chr9 5122984 5123141 2337.50 EX21 6457.1 
JAK2_Cds_17087554_UserDefined (47229383)_140706991 chr9 5029763 5029926 4415.00 EX2 6457.1 
JAK2_Cds_17087712_UserDefined (47229389)_140707003 chr9 5069905 5070072 1260.50 EX10 6457.1 
JAK2_Cds_17087860_UserDefined (47132148)_140706998 chr9 5064863 5065060 4233.50 EX7 6457.1 
JAK2_Cds_17087860_UserDefined (47132148)_140706999 chr9 5064863 5065060 831.00 EX7 6457.1 
JAK2_Cds_17087904_UserDefined (47132154)_140707006 chr9 5077433 5077600 4535.50 EX13 6457.1 
JAK2_Cds_17087904_UserDefined (47132154)_140707007 chr9 5077433 5077600 868.50 EX13 6457.1 
JAK2_Cds_17088449_UserDefined (47132152)_140707004 chr9 5072472 5072646 2390.50 EX11 6457.1 
JAK2_Cds_17088454_UserDefined (47229390)_140707005 chr9 5073678 5073805 4408.50 EX12 6457.1 
JAK2_Cds_17088950_UserDefined (47229384)_140706992 chr9 5044383 5044540 7850.00 EX3 6457.1 
JAK2_Cds_17089173_UserDefined (47229391)_140707008 chr9 5078286 5078464 2013.00 EX14 6457.1 
JAK2_Cds_17089231_UserDefined (47229386)_140706995 chr9 5054543 5054904 711.00 EX5 6457.1 
JAK2_Cds_17089231_UserDefined (47229386)_140706996 chr9 5054543 5054904 2713.00 EX5 6457.1 
JAK2_Cds_17090261_UserDefined (47132150)_140707001 chr9 5069002 5069228 5903.00 EX9 6457.1 
JAK2_Cds_17090261_UserDefined (47132150)_140707002 chr9 5069002 5069228 4175.50 EX9 6457.1 
JAK2_Cds_17091284_UserDefined (47229387)_140706997 chr9 5055649 5055808 1269.50 EX6 6457.1 
JAK2_Cds_17091671_UserDefined (47229388)_140707000 chr9 5066658 5066809 330.00 Ex8 6457.1 
JAK3 + JAK3 + JAK3_UserDefined (47132137)_140706967 chr19 17953816 17954729 607.50 EX2,3,4 12366.1 
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JAK3 + JAK3 + JAK3_UserDefined (47132137)_140706968 chr19 17953816 17954729 1720.50 EX2,3,4 12366.1 
JAK3 + JAK3 + JAK3_UserDefined (47132137)_140706969 chr19 17953816 17954729 5329.00 EX2,3,4 12366.1 
JAK3 + JAK3 + JAK3_UserDefined (47132137)_140706970 chr19 17953816 17954729 1962.50 EX2,3,4 12366.1 
JAK3 + JAK3 + JAK3_UserDefined (47132137)_140706971 chr19 17953816 17954729 5370.00 EX2,3,4 12366.1 
JAK3 + JAK3 + JAK3_UserDefined (47229377)_140706957 chr19 17945360 17946044 3898.50 EX14,15,16 12366.1 
JAK3 + JAK3 + JAK3_UserDefined (47229377)_140706958 chr19 17945360 17946044 4453.00 EX14,15,16 12366.1 
JAK3 + JAK3 + JAK3_UserDefined (47229377)_140706959 chr19 17945360 17946044 6911.50 EX14,15,16 12366.1 
JAK3 + JAK3 + JAK3_UserDefined (47229377)_140706960 chr19 17945360 17946044 3776.00 EX14,15,16 12366.1 
JAK3 + JAK3_UserDefined (47132131)_140706947 chr19 17940897 17941449 88.50 EX21,22 12366.1 
JAK3 + JAK3_UserDefined (47132131)_140706948 chr19 17940897 17941449 31.00 EX21,22 12366.1 
JAK3 + JAK3_UserDefined (47132131)_140706949 chr19 17940897 17941449 1424.00 EX21,22 12366.1 
JAK3 + JAK3_UserDefined (47132133)_140706954 chr19 17943308 17943758 1471.00 EX17,18 12366.1 
JAK3 + JAK3_UserDefined (47132133)_140706955 chr19 17943308 17943758 355.50 EX17,18 12366.1 
JAK3 + JAK3_UserDefined (47132133)_140706956 chr19 17943308 17943758 1707.00 EX17,18 12366.1 
JAK3 + JAK3_UserDefined (47132135)_140706961 chr19 17948721 17949219 7354.50 EX10,11 12366.1 
JAK3 + JAK3_UserDefined (47132135)_140706962 chr19 17948721 17949219 4540.50 EX10,11 12366.1 
JAK3 + JAK3_UserDefined (47132135)_140706963 chr19 17948721 17949219 5699.00 EX10,11 12366.1 
JAK3 + JAK3_UserDefined (47229376)_140706950 chr19 17942017 17942627 3947.50 EX19,20 12366.1 
JAK3 + JAK3_UserDefined (47229376)_140706951 chr19 17942017 17942627 626.00 EX19,20 12366.1 
JAK3 + JAK3_UserDefined (47229376)_140706952 chr19 17942017 17942627 64.00 EX19,20 12366.1 
JAK3 + JAK3_UserDefined (47229376)_140706953 chr19 17942017 17942627 2191.50 EX19,20 12366.1 
JAK3 + JAK3_UserDefined (47229378)_140706964 chr19 17952178 17952591 6383.00 EX6,7 12366.1 
JAK3 + JAK3_UserDefined (47229378)_140706965 chr19 17952178 17952591 711.50 EX6,7 12366.1 
JAK3 + JAK3_UserDefined (47229378)_140706966 chr19 17952178 17952591 572.50 EX6,7 12366.1 
JAK3_Cds_16875134_UserDefined (47229397)_140707016 chr19 17953105 17953439 4232.50 EX5 12366.1 
JAK3_Cds_16875134_UserDefined (47229397)_140707017 chr19 17953105 17953439 1160.50 EX5 12366.1 
JAK3_Cds_16876878_UserDefined (47131220)_140707014 chr19 17947918 17948042 251.50 EX12 12366.1 
JAK3_Cds_16877020_UserDefined (47229395)_140707013 chr19 17946713 17946880 397.00 EX13 12366.1 
JAK3_Cds_16877924_UserDefined (47132127)_140706939 chr19 17950274 17950639 1674.50 EX9 12366.1 
JAK3_Cds_16877924_UserDefined (47132127)_140706940 chr19 17950274 17950639 5601.50 EX9 12366.1 
JAK3_Cds_16877924_UserDefined (47132127)_140706941 chr19 17950274 17950639 1461.50 EX9 12366.1 
JAK3_Cds_16878504_UserDefined (47229398)_140707018 chr19 17955023 17955246 1238.50 EX1 12366.1 
JAK3_Cds_16878504_UserDefined (47229398)_140707019 chr19 17955023 17955246 1417.00 EX1 12366.1 
JAK3_Cds_16879644_UserDefined (47229373)_140706938 chr19 17937543 17937924 3472.50 EX23 12366.1 
JAK3_Cds_16880177_UserDefined (47229396)_140707015 chr19 17951019 17951170 6106.50 EX8 12366.1 
KRAS_Cds_16746132_UserDefined (47229450)_140707104 chr12 25362712 25362865 859.00 Ex4 8702.1 
KRAS_Cds_16746135_UserDefined (47132216)_140707105 chr12 25368358 25368514 8414.00 EX4 8703.1 
KRAS_Cds_16746575_UserDefined (47229400)_140707021 chr12 25380148 25380366 7348.00 Ex2 8702.1 
KRAS_Cds_16746575_UserDefined (47229400)_140707022 chr12 25380148 25380366 6820.00 EX2 8702.1 
KRAS_Cds_16746855_UserDefined (47229399)_140707020 chr12 25378528 25378727 1316.00 EX3 8702.1 
KRAS_Cds_16749892_UserDefined (47229381)_140706986 chr12 25398188 25398338 2348.00 EX1 8702.1 
NRAS_Cds_16673855_UserDefined (47229424)_140707057 chr1 115258651 11525880
1 
5145.50 Ex1 877.1 
NRAS_Cds_16676341_UserDefined (47229423)_140707055 chr1 115256401 11525661
9 
758.00 Ex2 877.1 
NRAS_Cds_16676341_UserDefined (47229423)_140707056 chr1 115256401 11525661
9 
392.50 Ex2 877.1 
NRAS_Cds_16677908_UserDefined (47229422)_140707054 chr1 115252170 11525236
9 
778.00 Ex3 877.1 
NRAS_Cds_16678533_UserDefined (47229452)_140707107 chr1 115251139 11525129
5 
4885.00 Ex4 877.1 
PTPN11 + PTPN11_UserDefined (47132141)_140706983 chr12 112915435 11291583
9 
5164.50 EX8,9 9163.1 
PTPN11 + PTPN11_UserDefined (47132141)_140706984 chr12 112915435 11291583
9 
4770.00 EX8,9 9163.1 
PTPN11 + PTPN11_UserDefined (47132141)_140706985 chr12 112915435 11291583
9 
9136.00 EX8,9 9163.1 
PTPN11 + PTPN11_UserDefined (47132214)_140707103 chr12 112924259 11292445
4 
4029.50 EX11 9163.1 
PTPN11_Cds_16763256_UserDefined (47229418)_140707049 chr12 112910728 11291086
4 
2483.50 EX7 9163.1 
PTPN11_Cds_16764105_UserDefined (47229416)_140707043 chr12 112888102 11288833
6 
318.00 EX3 9163.1 
PTPN11_Cds_16764105_UserDefined (47229416)_140707044 chr12 112888102 11288833
6 
5040.50 EX3 9163.1 
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PTPN11_Cds_16764883_UserDefined (47229419)_140707051 chr12 112926227 11292633
4 
5671.50 EX12 9163.1 
PTPN11_Cds_16765751_UserDefined (47131242)_140707048 chr12 112893734 11289388
7 
5584.50 EX6 9163.1 
PTPN11_Cds_16765752_UserDefined (47131244)_140707050 chr12 112919858 11292002
9 
5056.00 EX10 9163.1 
PTPN11_Cds_16766151_UserDefined (47229417)_140707047 chr12 112892348 11289250
4 
3610.50 EX5 9163.1 
PTPN11_Cds_16766381_UserDefined (47229414)_140707041 chr12 112856896 11285694
9 
208.00 EX1 9163.1 
PTPN11_Cds_16766939_UserDefined (47229451)_140707106 chr12 112942479 11294258
5 
3349.50 EX15 9163.1 
PTPN11_Cds_16766945_UserDefined (47131248)_140707045 chr12 112890979 11289121
1 
10530.50 EX4 9163.1 
PTPN11_Cds_16766945_UserDefined (47131248)_140707046 chr12 112890979 11289121
1 
637.00 EX4 9163.1 
PTPN11_Cds_16767137_UserDefined (47229420)_140707052 chr12 112926808 11292699
9 
3461.00 EX13 9163.1 
PTPN11_Cds_16767501_UserDefined (47229421)_140707053 chr12 112939928 11294008
0 
4683.50 EX14 9163.1 
PTPN11_Cds_16767914_UserDefined (47229415)_140707042 chr12 112884060 11288422
2 
3707.50 EX2 9163.1 
 
 
Supplemental Table 6. Univariate analyses for CR achievement, considering clinically 
relevant variables and molecular prognostic markers. 
 
 Univariate analysis for CR 
 OR (95%CI) p-value 
Ph-like vs non-Ph-like 0.265 (0.071-0.921) 0.038 
Age 0.995 (0.958-1.033) 0.788 
WBC 0.989 (0.977-1) 0.062 
Plts 1 (0.994-1.008) 0.924 
Hb 1.36 (1.011-1.89) 0.051 
F vs M 1.898 (0.589-7.313) 0.306 
No SR vs SR 0.311 (0.085-1.059) 0.063 
   
IKZF1+ CDKN2A/2B and/or PAX5 vs IKZF1-only/WT 0.362 (0.101-1.37) 0.119 
Cell cycle genes deletion vs WT 1.895 (0.547-7.605) 0.329 
RAS clonal vs WT/M subclonal 3.125 (0.757-21.247) 0.158 
JAK/STAT clonal vs WT/M subclonal 0.571 (0.12-4.139) 0.515 
 Supplemental Figure 1. Scheme of GIMEMA LAL1913 clinical trial. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 115 B-NEG ALL patients enrolled 
105 with biological material available 
88 evaluated for Ph-like predictor 85 studied 
by RNA-seq 
Supplemental Figure 2: Consort diagram summarizing the biological analyses carried out. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 evaluated for 
NGS 
91 studied for NGS 
87 studied for MLPA 
15 evaluated 
for 
MLPA and 
NGS 
70 evaluated for Ph-like 
predictor, NGS, RNA-seq 
and/or FISH and MLPA 
15 evaluated for 
Ph-like predictor 
and RNA- seq 
3 evaluated 
for Ph-like 
predictor 
only 
91 with DNA available 88 with RNA available 
 Supplemental Figure 3: OS of Ph-like (red line, n=27) vs non-Ph-like (n=59). 
 
 
 
 
 
 
 
 
 
 
